California Public Employees Retirement System reduced its position in shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) by 3.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 212,100 shares of the biopharmaceutical company’s stock after selling 6,600 shares during the period. California Public Employees Retirement System owned 0.17% of Halozyme Therapeutics worth $1,830,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. IFP Advisors Inc raised its position in shares of Halozyme Therapeutics by 300.8% in the first quarter. IFP Advisors Inc now owns 11,366 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 8,530 shares during the last quarter. Meeder Asset Management Inc. bought a new position in Halozyme Therapeutics during the second quarter valued at about $155,000. M&T Bank Corp bought a new position in Halozyme Therapeutics during the first quarter valued at about $304,000. Kennedy Capital Management Inc. raised its position in Halozyme Therapeutics by 4.0% in the first quarter. Kennedy Capital Management Inc. now owns 73,681 shares of the biopharmaceutical company’s stock valued at $698,000 after buying an additional 2,818 shares in the last quarter. Finally, ClariVest Asset Management LLC raised its position in Halozyme Therapeutics by 15.4% in the second quarter. ClariVest Asset Management LLC now owns 91,204 shares of the biopharmaceutical company’s stock valued at $787,000 after buying an additional 12,200 shares in the last quarter. Hedge funds and other institutional investors own 80.41% of the company’s stock.
Shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) traded down 1.65% during mid-day trading on Friday, reaching $11.92. The company had a trading volume of 1,035,448 shares. The firm’s market capitalization is $1.53 billion. Halozyme Therapeutics Inc. has a one year low of $6.96 and a one year high of $18.65. The stock has a 50 day moving average of $11.11 and a 200-day moving average of $10.07.
Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.06. Halozyme Therapeutics had a negative net margin of 44.90% and a negative return on equity of 234.15%. The business earned $33.30 million during the quarter, compared to the consensus estimate of $29.94 million. During the same period in the previous year, the business earned $0.02 earnings per share. The company’s revenue was down 23.3% on a year-over-year basis. Equities analysts predict that Halozyme Therapeutics Inc. will post ($0.91) EPS for the current year.
Several research analysts have recently issued reports on HALO shares. Wells Fargo & Co. restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, September 8th. Piper Jaffray Cos. raised their price target on Halozyme Therapeutics from $15.00 to $18.00 and gave the stock an “overweight” rating in a research report on Friday, September 16th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $16.11.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.